Table 3.

Therapeutic management and clinical and virological response to therapy of the 60 patients with systemic vasculitis and chronic active HCV infection according to presence or absence of detectable MC. Except where indicated otherwise, values are no. (%).

FeatureCases MC–, n = 12Controls MC+, n = 48Unadjusted OR (95% CI)p
Treatment of vasculitis
  Antiviral therapy, n (%)10 (83)44 (92)0.5 (0.1–2.7)0.4
    IFN α-2b plus ribavirin321
    PEG-IFN α-2b plus ribavirin723
  Corticosteroids, n (%)8 (67)19 (40)3.3 (0.8–13.8)0.08
  Plasmapheresis, n (%)1 (8)12 (25)0.3 (0.03–2.4)0.2
  Cyclophosphamide, n (%)1 (8)4 (8)1 (0.1–10.1)1
  Rituximab, n (%)2 (17)11 (23)0.7 (0.1–3.4)0.6
Clinical response of the vasculitis, n (%)0.05
  Complete response5 (42)35 (73)0.3 (0.04–1.9)
  Partial response4 (33)5 (10)
  Nonresponder3 (25)8 (17)1
HCV virological response
  Sustained virologic response, n (%)4/10 (40)28/44 (64)0.4 (0.1–1.9)0.3